In efforts to determine the mechanisms of action of Tat
To assess the biological relevance of the PCAF bromodomain and Tat interaction to the activation of Tat in transactivation of HIV-1 transcription, we investigated whether the interaction of the activated, lysine-acettranscriptional activity by PCAF and p300/CBP (Benkirane et al., 1998; Kiernan et al., 1999), we performed cell ylated Tat with the nuclear HAT transcriptional cofactors p300/CBP and PCAF involves any of the bromodomains transfection experiments and measured their combined effect on the activity of the HIV-1 promoter using an of the latter proteins. Here, we report that the bromodomain of PCAF but not CBP can specifically recognize HIV-1 LTR-luciferase reporter gene assay (Bieniasz et al., 1998; Madore and Cullen, 1993). As shown in Figure the lysine-acetylated Tat at K50 (not K51 or K28), and this interaction competes effectively against TAR RNA 1C, synergistic activation of Tat-mediated transcription of the HIV-1 promoter in human 293T cells is dependent binding to the acetylated Tat. We have also determined the three-dimensional structure of the PCAF bromodoupon both PCAF and CBP. The latter HAT transcriptional coactivator has been recently shown to be responsible main in complex with a lysine-acetylated peptide derived from Tat at K50 by using nuclear magnetic resofor lysine acetylation of Tat at K50 that is required for Tat To understand the structural basis of this molecular recognition, we determined the three-dimensional structure (SYGR-AcK-KRRQR, where AcK is an N ⑀ -acetyl-lysine) showed no detectable interactions with either bromodoof the PCAF bromodomain in complex with Tat AcK50 peptide from a total of 2903 NMR-derived restraints. mains or bromodomain and PHD finger (Aasland et al., 1995) tandem modules from CBP or TIF1␤ (transcripThe structure for the protein (residues 723-830) and the peptide (residues 47-54) complex was well defined by tional intermediary factor 1␤, also named KAP-1 and KRIP-1) (Friedman et al., 1996) ( Figure 1A) . Strikingly, the NMR data ( Figure 2A , Table 1 ). The structure of the bromodomain when complexed to the Tat peptide the same Tat peptide bound tightly to the bromodomain of PCAF, which shares high sequence homology to CBP consists of a left-handed four-helix bundle (helices ␣ Z , ␣ A , ␣ B , and ␣ C ) and is similar to its free form structure bromodomain (Jeanmougin et http://www.molecule.org/cgi/content/full/9/3/575/ portant to note that since both V763 and E756 are solvent exposed and located in loop regions of the struc-DC1). Together, our NMR data strongly suggest that conformational changes of protein residues in the ligand ture ( Figure 2D ), their individual mutation to alanine binding site are directly coupled with the highly selective unlikely causes major conformational disruption of the interactions between PCAF bromodomain and acetprotein. Mutation results of these protein residues are ylated Tat. consistent with the NMR structure of the complex and confirm their direct interactions with the acetyl-lysine and/or its flanking residues in the Tat peptide.
Specificity of PCAF Bromodomain
To further identify determinants in Tat sequence for and Tat Recognition PCAF bromodomain recognition, we synthesized muTo determine the relative contributions of bromodomain tant peptides and tested their binding to the protein residues in Tat binding site ( Figure 3A) , we examined its in a peptide competition assay. Because of the high mutant proteins for binding to an N-terminal biotinylated sensitivity of this detection method, the binding study Tat AcK50 peptide immobilized onto streptavidin agawas performed at a protein concentration (10 M) much rose beads. Mutation of bromodomain residues W746, lower than that required for NMR study ‫002ف(‬ M), en-E750, T755, I764, D769, N798, C799, or N803 to alanine suring specificity of protein-peptide interactions. As andid not affect peptide binding, whereas proteins conticipated, lysine-acetylated peptides derived from Tat taining an alanine mutation at F748, V752, Y802, or Y809 at K51 or K28 (lanes 11 and 12 in Figure 3C ) or from showed a major reduction or nearly complete loss in Tat 
